1337918-83-8

1337918-83-8 structure

Name: Vazegepant
Chemical Name: N-{(2R)-3-(7-Methyl-1H-indazol-5-yl)-1-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-1-oxo-2-propanyl}-4-(2-oxo-1,2-dihydro-3-quinolinyl)-1-piperidinecarboxamide
CAS Number: 1337918-83-8
Molecular Formula: C₃₆H₄₆N₈O₃
Molecular Weight: 638.80
Catalog: Signaling Pathways GPCR/G Protein CGRP Receptor
Create Date: 2021-12-19 11:58:43
Modify Date: 2025-08-25 13:24:58
Vazegepant is the first intranasal CGRP receptor antagonist for the study the acute research of migraine[1][2].

Name	N-{(2R)-3-(7-Methyl-1H-indazol-5-yl)-1-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-1-oxo-2-propanyl}-4-(2-oxo-1,2-dihydro-3-quinolinyl)-1-piperidinecarboxamide
Synonyms	1-Piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-N-[(1R)-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]- N-{(2R)-3-(7-Methyl-1H-indazol-5-yl)-1-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-1-oxo-2-propanyl}-4-(2-oxo-1,2-dihydro-3-quinolinyl)-1-piperidinecarboxamide

Description	Vazegepant is the first intranasal CGRP receptor antagonist for the study the acute research of migraine[1][2].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> CGRP Receptor Signaling Pathways >> Neuronal Signaling >> CGRP Receptor Research Areas >> Neurological Disease
References	[1]. Leonard KA, et al. Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2020 Mar 26;63(6):2915-2929. [2]. Gene M Dubowchik,Charles M Conway,Alison W Xin.Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success.